Treatment of multiple sclerosis in children and its challenges

La Presse médicale
Sona Narula, Brenda Banwell

Abstract

Though pediatric-onset multiple sclerosis (MS) is a rare disease, providers must be aware of the diagnosis, and of symptoms that herald demyelination, in order to initiate prompt workup and treatment in the appropriate clinical scenarios. Though children with MS do not have significant physical disability at onset, at least a third of patients have cognitive deficits at the time of diagnosis and demonstrate worsening cognitive functioning over time. Pediatric MS patients tend to have high relapse rates and high lesion volumes early in their disease course and warrant early initiation of disease modifying therapy. This review discusses the different treatment options available for pediatric patients with MS, emerging medications, and some of the challenges associated with treating this patient population.

References

Oct 9, 2002·Neurology·A BoikoUNKNOWN University of British Columbia MS Clinic Neurologists
Mar 9, 2005·Neurology·Brenda L Banwell, Peter E Anderson
Apr 27, 2005·Neurology·George P A RicePeter A Calabresi
Jan 3, 2006·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·A Ghezzi, UNKNOWN Immunomodulatory Treatment of Early Onset MS (ITEMS) Group
Mar 3, 2006·The New England Journal of Medicine·Chris H PolmanUNKNOWN AFFIRM Investigators
Apr 25, 2006·Annals of Neurology·Olaf StüveMichael K Racke
Jun 16, 2006·Neurology·Silvia N Tenembaum, Martin J Segura
Jun 22, 2007·The New England Journal of Medicine·Christel RenouxUNKNOWN Adult Neurology Departments KIDMUS Study Group
Oct 9, 2007·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Martin S WeberScott S Zamvil
Apr 15, 2008·European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society·Giovanna BorrielloCarlo Pozzilli
Dec 10, 2008·Archives of Neurology·Peter HuppkeJutta Gärtner
Jan 14, 2009·Archives of Neurology·Mark P GormanTanuja Chitnis
May 15, 2009·Neurology·N MakhaniT Chitnis
Jul 11, 2009·Pediatric Neurology·Jennifer E ThannhauserLuanne M Metz
Feb 4, 2010·Neurology·D ChabasUNKNOWN US Network of Pediatric MS Centers of Excellence
Oct 13, 2010·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·A GhezziM P Amato
Dec 24, 2010·Therapeutic Advances in Neurological Disorders·E Ann Yeh, Bianca Weinstock-Guttman
Mar 10, 2011·Annals of Neurology·Chris H PolmanJerry S Wolinsky
Dec 8, 2011·Multiple Sclerosis : Clinical and Laboratory Research·T ChitnisUNKNOWN International Pediatric Multiple Sclerosis Study Group
Nov 17, 2012·Journal of Child Neurology·Laura JulianUNKNOWN Network of Pediatric MS Centers of Excellence
Feb 13, 2013·Multiple Sclerosis : Clinical and Laboratory Research·A GhezziUNKNOWN Italian MS Study Group

❮ Previous
Next ❯

Citations

Aug 13, 2015·Human Vaccines & Immunotherapeutics·Giovanna VitalitiRaffaele Falsaperla
Apr 1, 2015·La Presse médicale·David-Axel Laplaud
Nov 23, 2016·Neurodegenerative Disease Management·Sona Narula
Dec 3, 2016·Expert Opinion on Pharmacotherapy·Emanuele D'AmicoFrancesco Patti
Dec 15, 2017·BioMed Research International·Nedia Ben AchourIlhem Ben Youssef Turki

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.